Advertisement

Glycosaminoglycan Functionalized Nanoparticles Exploit Glycosaminoglycan Functions

  • James A. Vassie
  • John M. Whitelock
  • Megan S. LordEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1229)

Abstract

Nanoparticles are being explored for a variety of applications including medical imaging, drug delivery, and biochemical detection. Surface functionalization of nanoparticles with glycosaminoglycans (GAGs) is an attractive strategy that is only starting to be investigated to improve their properties for biological and therapeutic applications. Herein, we describe a method to functionalize the surface of cerium oxide nanoparticles (nanoceria) with organosilane linkers, such as 3-(aminopropyl)triethoxysilane (APTES) and 3-(mercaptopropyl)trimethoxysilane (MPTMS), and GAGs, such as unfractionated and low molecular weight heparin. Examples of how the activity of these heparin functionalized nanoparticles are governed by the pendant GAGs are detailed. The activity of heparin covalently attached to the nanoceria was found to be unchanged when compared to unfractionated heparin using the activated partial clotting time (APTT) assay.

Key words

Nanoparticle Cerium oxide Heparin Glycosaminoglycan Organosilane linker 

Notes

Acknowledgement

This work was supported by the Australian Research Council Discovery Project scheme.

References

  1. 1.
    Reyes-Ortega F, Rodríguez G, Aguilar MR, Lord M, Whitelock J, Stenzel MH, San Román J (2013) Encapsulation of low molecular heparin (bemiparin) into polymeric nanoparticles obtained from cationic block copolymers: properties and cell activity. J Mater Chem B 1:850–860CrossRefGoogle Scholar
  2. 2.
    Zhao Y, Lord MS, Stenzel MH (2013) A polyion complex micelle with heparin for growth factor delivery and uptake into cells. J Mater Chem B 1:1635–1643CrossRefGoogle Scholar
  3. 3.
    Ting SRS, Whitelock JM, Tomic R, Gunawan C, Teoh WY, Amal R et al (2013) Cellular uptake and activity of heparin functionalised cerium oxide nanoparticles in monocytes. Biomaterials 34:4377–44386PubMedCrossRefGoogle Scholar
  4. 4.
    Lord MS, Tsoi B, Gunawan C, Teoh WY, Amal R, Whitelock JM (2013) Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles. Biomaterials 28:8888–8999Google Scholar
  5. 5.
    Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455–482PubMedCrossRefGoogle Scholar
  6. 6.
    Yuk SH, Oh KS, Cho SH, Lee BS, Kim SY, Kwak BK et al (2011) Glycol chitosan/heparin immobilized iron oxide nanoparticles with a tumor-targeting characteristic for magnetic resonance imaging. Biomacromolecules 12:2335–2343PubMedCrossRefGoogle Scholar
  7. 7.
    Lord MS, Jung M, Teoh WY, Gunawan C, Vassie JA, Amal R et al (2012) Cellular uptake and reactive oxygen species modulation of cerium oxide nanoparticles in human monocyte cell line U937. Biomaterials 33:7915–7924PubMedCrossRefGoogle Scholar
  8. 8.
    Nilasaroya A, Poole-Warren LA, Whitelock JM, Martens PJ (2008) Structural and functional characterisation of poly(vinyl alcohol) and heparin hydrogels. Biomaterials 29:4658–4664PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • James A. Vassie
    • 1
  • John M. Whitelock
    • 1
  • Megan S. Lord
    • 1
    Email author
  1. 1.Graduate School of Biomedical EngineeringThe University of New South WalesSydneyAustralia

Personalised recommendations